Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster modelAntimicrobial agents and chemotherapy (2011)
AbstractInterferon (IFN) is an innate immune response protein that is involved in the antiviral response during viral infection. Treatment of acute viral infections with exogenous interferon may be effective but is generally not feasible for clinical use due to many factors, including cost, stability, and availability. To overcome these limitations, an adenovirus type 5-vectored consensus alpha IFN, termed DEF201, was constructed as a potential way to deliver sustained therapeutic levels of systemic IFN. To demonstrate the efﬁcacy of DEF201 against acute ﬂaviviral disease, various concentrations of the construct were administered as a single intranasal dose prior to virus infection, which resulted in a dose-responsive, protective effect in a hamster model of yellow fever virus (YFV) disease. A DEF201 dose of 5 x 107 PFU/animal administered intranasally just prior to YFV challenge protected 100% of the animals, while a 10-fold lower DEF201 dose exhibited lower, although signiﬁcant, levels of protection. Virus titers in the liver and serum and levels of serum alanine aminotransferase were all signiﬁcantly reduced as a result of DEF201 administration at all doses tested. No toxicity, as indicated by weight loss or gross morbidity, was observed in non-YFV-infected animals treated with DEF201. Protection of YFV-infected animals was observed when DEF201 was delivered as early as 7 days prior to virus challenge and as late as 2 days after virus challenge, demonstrating effective prophylaxis and therapy in a hamster model of disease. Overall, it appears that DEF201 is effective in the treatment of YFV in a hamster model.
- hamster model,
- yellow fever,
Publication DateJanuary 1, 2011
Citation InformationJulander, J. G., J. Ennis, J. Turner, and J. D. Morrey. 2011. Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrobial agents and chemotherapy 55:2067-2073. PMID21300837 PMC3088275